Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

2.

Dr. Prerana S. Nesargi's message for Childhood Cancer Awareness Month 2023 is to increase understanding of pediatric oncology.

3.

Inner Thoughts of Leonard Bernstein, the "Maestro".

4.

Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.

5.

HER3 Antibody Drug Conjugate Shows Promise in NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot